In:
Bioanalysis, Future Science Ltd, Vol. 9, No. 19 ( 2017-10), p. 1451-1463
Abstract:
Aim: Denosumab is a recombinant fully human IgG2 that has a high affinity and specificity for human RANKL. Commercially available RANKL labeled with an Fc fragment cannot be used to establish an indirect ELISA. To characterize denosumab pharmacokinetic a robust and accuracy method should be developed urgently. Results: In this study, an immunoaffinity enrichment method coupled with LC–MS/MS was established. The LC–MS/MS method acquired a linear range from 0.1 to 30 μg/ml. The intra- and inter-run precision (CV%) was within 11.5 and 10.5%, respectively. More importantly, the LC–MS/MS pharmacokinetic data were consistent with ELISA. Conclusion: This approach accelerated the quantification, reduced the costs and provided an alternative in case of lacking the special antigen to denosumab or a RANKL-biotinylated reagent.
Type of Medium:
Online Resource
ISSN:
1757-6180
,
1757-6199
DOI:
10.4155/bio-2017-0106
Language:
English
Publisher:
Future Science Ltd
Publication Date:
2017
SSG:
15,3
Permalink